biostudies-literatureUnknown9(92)Yanagihara KPoorly differentiated neuroendocrine carcinoma of the duodenum (D-NEC) is a rare cancer with poor prognosis. However, a D-NEC cell line has not yet been established to study the disease. We established a cell line, TCC-NECT-2, from the ascites tumor of a 59-year-old male Japanese patient with D-NEC. TCC-NECT-2 was positive for neuroendocrine markers, chromogranin A (CGA), cluster of differentiation 56 (CD56/NCAM), synaptophysin (SYN/p38), and neuron specific enolase (NSE). Cells exhibited retinoblastoma (RB) protein loss. Orthotopic implantation of TCC-NECT-2 cells into nu/nu mice resulted in tumor formation (incidence = 83.3%) with neuroendocrine characteristics, metastasis, and weight loss. BRAF^V600E and TP53 mutations and C-MYC gene amplification were also observed in TCC-NECOncotarget36503-36514https://www.ebi.ac.uk/biostudies/studies/S-EPMC6284856biostudies-literatureEstablishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma.PMC6284856Kubo TYanagihara KMihara KSeyama TYokozaki HKuwata TOchiai AfalseEstablishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma.Poorly differentiated neuroendocrine carcinoma of the duodenum (D-NEC) is a rare cancer with poor prognosis. However, a D-NEC cell line has not yet been established to study the disease. We established a cell line, TCC-NECT-2, from the ascites tumor of a 59-year-old male Japanese patient with D-NEC. TCC-NECT-2 was positive for neuroendocrine markers, chromogranin A (CGA), cluster of differentiation 56 (CD56/NCAM), synaptophysin (SYN/p38), and neuron specific enolase (NSE). Cells exhibited retinoblastoma (RB) protein loss. Orthotopic implantation of TCC-NECT-2 cells into nu/nu mice resulted in tumor formation (incidence = 83.3%) with neuroendocrine characteristics, metastasis, and weight loss. BRAF^V600E and TP53 mutations and C-MYC gene amplification were also observed in TCC-NEC2018-01-01T00:00:00Z2018 Nov2026-07-16T16:37:59.378Z2019-03-27T00:12:52ZS-EPMC62848563055993310.18632/oncotarget.26367